LL-37 for Rosacea and Skin Conditions: The Cathelicidin Research
The persistent redness, flushing, and inflammatory papules of rosacea affect an estimated 16 million Americans, yet the underlying pathophysiology remained poorly understood for decades. A breakthrough came when researchers identified a specific antimicrobial peptide — cathelicidin LL-37 — as a central mediator of the disease. This discovery has reshaped our understanding of rosacea as an innate immune disorder and opened new avenues for peptide-focused research.
What makes this story particularly fascinating is the paradox at its core: LL-37 is essential for skin defense against infection, yet its dysregulation appears to directly drive one of the most common dermatological conditions in the world.
What Is LL-37?
LL-37 is the only cathelicidin-derived antimicrobial peptide found in humans. It is produced by cleavage of the precursor protein hCAP18 (human cationic antimicrobial protein 18 kDa) and consists of 37 amino acids beginning with two leucine residues — hence the name. The peptide is expressed by keratinocytes, neutrophils, mast cells, and various other immune cells throughout the body.
Beyond its direct antimicrobial activity against bacteria, viruses, and fungi, LL-37 functions as a multifaceted immunomodulator. It promotes angiogenesis, recruits immune cells, modulates cytokine production, and influences wound healing. Vandamme et al., 2012 published a comprehensive review characterizing LL-37 as a true "alarmin" — a molecule that bridges innate and adaptive immunity.
The peptide adopts an amphipathic alpha-helical structure in physiological conditions, which allows it to interact with both cell membranes and a variety of receptors including formyl peptide receptor 2 (FPR2), P2X7, and EGFR. This receptor promiscuity underlies its diverse biological activities and helps explain its involvement in multiple skin conditions.
The Rosacea Connection
The pivotal link between LL-37 and rosacea was established by Yamasaki et al., 2007 in a landmark study published in Nature Medicine. The researchers demonstrated that patients with rosacea express abnormally high levels of cathelicidin in their facial skin, and — critically — that the cathelicidin peptides are processed into distinct, abnormal forms not found in healthy skin.
In normal skin, hCAP18 is cleaved by serine proteases to produce functional LL-37. In rosacea-affected skin, the serine protease kallikrein 5 (KLK5) is overexpressed, generating cathelicidin fragments with uniquely pro-inflammatory and pro-angiogenic properties. When these abnormal peptide fragments were injected into mouse skin, they reproduced the hallmark features of rosacea: redness, inflammation, and vascular dilation.
This finding was transformative. It reframed rosacea not merely as a vascular disorder but as a disease of dysregulated innate immune signaling, with aberrant cathelicidin processing as a central mechanism. Two et al., 2014 further demonstrated that LL-37 fragments promote inflammation in rosacea through activation of inflammasome pathways and mast cell degranulation.
Kallikrein 5 and the Protease Cascade
The enzyme KLK5 has emerged as a critical upstream regulator in this pathway. Yamasaki et al., 2006 showed that KLK5 expression is significantly elevated in rosacea skin compared to healthy controls. This protease cleaves hCAP18 into peptide fragments that differ from canonical LL-37 and exhibit enhanced inflammatory signaling.
Importantly, the vitamin D pathway regulates both cathelicidin and KLK5 expression. Schauber et al., 2007 demonstrated that vitamin D3 upregulates cathelicidin expression in keratinocytes through the vitamin D receptor, providing a potential mechanistic link between sun exposure (a well-known rosacea trigger) and disease flares. UV radiation activates vitamin D synthesis in the skin, which in turn drives cathelicidin production — potentially overwhelming the already dysregulated processing system in rosacea patients.
Other environmental triggers associated with rosacea — including heat, spicy food, alcohol, and emotional stress — may similarly converge on the cathelicidin-KLK5 axis, though the precise signaling pathways for each trigger remain under active investigation.
LL-37 in Other Skin Conditions
The cathelicidin story extends well beyond rosacea. Dysregulated LL-37 expression has been implicated in several other dermatological conditions:
This pattern suggests that cathelicidin functions along a "Goldilocks" spectrum: too little leaves the skin vulnerable to infection, while too much — or abnormally processed forms — drives inflammatory disease.
Therapeutic Research Directions
The identification of the cathelicidin-KLK5 axis has already influenced therapeutic development. The topical medication azelaic acid, long used empirically for rosacea, was subsequently shown to downregulate KLK5 and cathelicidin expression — providing a mechanistic explanation for its clinical efficacy. Del Rosso et al., 2013 reviewed the evidence supporting this mechanism of action.
Several research strategies are under exploration:
Muto et al., 2014 demonstrated in murine models that blocking the cathelicidin pathway could suppress rosacea-like inflammation, providing proof of concept for targeted therapeutic approaches. The challenge remains achieving localized modulation without compromising the peptide's essential antimicrobial functions in the skin.
Research into the skin microbiome has added another layer of complexity. Demodex folliculorum mites, which are found in higher densities on rosacea-affected skin, carry the bacterium Bacillus oleronius, which may itself trigger cathelicidin release and contribute to a self-amplifying inflammatory cycle. Lacey et al., 2007 first reported this microbial connection.
Current Limitations and Open Questions
Despite significant advances, several important questions remain unresolved. It is still unclear why cathelicidin dysregulation preferentially affects facial skin, though the higher density of sebaceous glands and Demodex mites in the central face may contribute. The genetic factors predisposing certain individuals to cathelicidin overexpression are also poorly characterized.
Additionally, most mechanistic research has been conducted in cell culture or murine models. While these systems have proven highly informative, the translation to human clinical interventions targeting the cathelicidin pathway specifically has been slow. No drug specifically designed to modulate LL-37 processing has yet reached late-stage clinical trials for rosacea.
The dual nature of LL-37 — protective against infection yet pathogenic when dysregulated — creates a fundamental therapeutic challenge. Any intervention must carefully calibrate its effects to avoid trading inflammatory disease for increased infection risk.